JP2022076151A - Oral composition with suppressed discoloration, and method for suppressing discoloration thereof - Google Patents
Oral composition with suppressed discoloration, and method for suppressing discoloration thereof Download PDFInfo
- Publication number
- JP2022076151A JP2022076151A JP2020186436A JP2020186436A JP2022076151A JP 2022076151 A JP2022076151 A JP 2022076151A JP 2020186436 A JP2020186436 A JP 2020186436A JP 2020186436 A JP2020186436 A JP 2020186436A JP 2022076151 A JP2022076151 A JP 2022076151A
- Authority
- JP
- Japan
- Prior art keywords
- discoloration
- oral composition
- ascorbic acid
- zinc
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 38
- 238000002845 discoloration Methods 0.000 title claims abstract description 35
- 238000000034 method Methods 0.000 title claims abstract description 14
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 76
- 235000010323 ascorbic acid Nutrition 0.000 claims abstract description 33
- 239000011668 ascorbic acid Substances 0.000 claims abstract description 33
- 229960005070 ascorbic acid Drugs 0.000 claims abstract description 33
- 150000003751 zinc Chemical class 0.000 claims abstract description 29
- 239000004386 Erythritol Substances 0.000 claims abstract description 18
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims abstract description 18
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims abstract description 18
- 235000019414 erythritol Nutrition 0.000 claims abstract description 18
- 229940009714 erythritol Drugs 0.000 claims abstract description 18
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims abstract description 18
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims abstract description 18
- 239000000811 xylitol Substances 0.000 claims abstract description 18
- 235000010447 xylitol Nutrition 0.000 claims abstract description 18
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims abstract description 18
- 229960002675 xylitol Drugs 0.000 claims abstract description 18
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims abstract description 17
- 239000000600 sorbitol Substances 0.000 claims abstract description 17
- 235000010356 sorbitol Nutrition 0.000 claims abstract description 17
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims abstract description 15
- 229960002920 sorbitol Drugs 0.000 claims abstract description 13
- 150000002505 iron Chemical class 0.000 claims description 28
- 239000008187 granular material Substances 0.000 claims description 8
- 150000007524 organic acids Chemical class 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 18
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 13
- 235000013305 food Nutrition 0.000 description 9
- 150000005846 sugar alcohols Chemical class 0.000 description 8
- 239000011701 zinc Substances 0.000 description 8
- 229910052725 zinc Inorganic materials 0.000 description 8
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 7
- 229910052742 iron Inorganic materials 0.000 description 7
- 235000015165 citric acid Nutrition 0.000 description 6
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 5
- -1 Iron salt Chemical class 0.000 description 5
- 229930003268 Vitamin C Natural products 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 235000019154 vitamin C Nutrition 0.000 description 5
- 239000011718 vitamin C Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 3
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000011706 ferric diphosphate Substances 0.000 description 3
- 235000007144 ferric diphosphate Nutrition 0.000 description 3
- CADNYOZXMIKYPR-UHFFFAOYSA-B ferric pyrophosphate Chemical compound [Fe+3].[Fe+3].[Fe+3].[Fe+3].[O-]P([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])([O-])=O CADNYOZXMIKYPR-UHFFFAOYSA-B 0.000 description 3
- 229940036404 ferric pyrophosphate Drugs 0.000 description 3
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 230000001953 sensory effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 239000011670 zinc gluconate Substances 0.000 description 3
- 235000011478 zinc gluconate Nutrition 0.000 description 3
- 229960000306 zinc gluconate Drugs 0.000 description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 150000000996 L-ascorbic acids Chemical class 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 235000019646 color tone Nutrition 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 235000020774 essential nutrients Nutrition 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 229960002413 ferric citrate Drugs 0.000 description 2
- 235000013924 ferrous gluconate Nutrition 0.000 description 2
- 239000004222 ferrous gluconate Substances 0.000 description 2
- 229960001645 ferrous gluconate Drugs 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 159000000014 iron salts Chemical class 0.000 description 2
- ATEAWHILRRXHPW-UHFFFAOYSA-J iron(2+);phosphonato phosphate Chemical compound [Fe+2].[Fe+2].[O-]P([O-])(=O)OP([O-])([O-])=O ATEAWHILRRXHPW-UHFFFAOYSA-J 0.000 description 2
- NPFOYSMITVOQOS-UHFFFAOYSA-K iron(III) citrate Chemical compound [Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NPFOYSMITVOQOS-UHFFFAOYSA-K 0.000 description 2
- VRIVJOXICYMTAG-IYEMJOQQSA-L iron(ii) gluconate Chemical compound [Fe+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O VRIVJOXICYMTAG-IYEMJOQQSA-L 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 239000000845 maltitol Substances 0.000 description 2
- 235000010449 maltitol Nutrition 0.000 description 2
- 229940035436 maltitol Drugs 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 239000011592 zinc chloride Substances 0.000 description 2
- 235000005074 zinc chloride Nutrition 0.000 description 2
- 229960001939 zinc chloride Drugs 0.000 description 2
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 2
- 229960001763 zinc sulfate Drugs 0.000 description 2
- 229910000368 zinc sulfate Inorganic materials 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- YNVZDODIHZTHOZ-UHFFFAOYSA-K 2-hydroxypropanoate;iron(3+) Chemical compound [Fe+3].CC(O)C([O-])=O.CC(O)C([O-])=O.CC(O)C([O-])=O YNVZDODIHZTHOZ-UHFFFAOYSA-K 0.000 description 1
- PVXPPJIGRGXGCY-DJHAAKORSA-N 6-O-alpha-D-glucopyranosyl-alpha-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@](O)(CO)O1 PVXPPJIGRGXGCY-DJHAAKORSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 239000005955 Ferric phosphate Substances 0.000 description 1
- PMVSDNDAUGGCCE-TYYBGVCCSA-L Ferrous fumarate Chemical compound [Fe+2].[O-]C(=O)\C=C\C([O-])=O PMVSDNDAUGGCCE-TYYBGVCCSA-L 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- CANRESZKMUPMAE-UHFFFAOYSA-L Zinc lactate Chemical compound [Zn+2].CC(O)C([O-])=O.CC(O)C([O-])=O CANRESZKMUPMAE-UHFFFAOYSA-L 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- FRHBOQMZUOWXQL-UHFFFAOYSA-L ammonium ferric citrate Chemical compound [NH4+].[Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FRHBOQMZUOWXQL-UHFFFAOYSA-L 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229960004642 ferric ammonium citrate Drugs 0.000 description 1
- 229960004887 ferric hydroxide Drugs 0.000 description 1
- 229940032958 ferric phosphate Drugs 0.000 description 1
- 229940032950 ferric sulfate Drugs 0.000 description 1
- 239000011640 ferrous citrate Substances 0.000 description 1
- 235000019850 ferrous citrate Nutrition 0.000 description 1
- 239000011773 ferrous fumarate Substances 0.000 description 1
- 235000002332 ferrous fumarate Nutrition 0.000 description 1
- 229960000225 ferrous fumarate Drugs 0.000 description 1
- 229960001781 ferrous sulfate Drugs 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000004313 iron ammonium citrate Substances 0.000 description 1
- 235000000011 iron ammonium citrate Nutrition 0.000 description 1
- FBAFATDZDUQKNH-UHFFFAOYSA-M iron chloride Chemical compound [Cl-].[Fe] FBAFATDZDUQKNH-UHFFFAOYSA-M 0.000 description 1
- 150000002506 iron compounds Chemical class 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- WBJZTOZJJYAKHQ-UHFFFAOYSA-K iron(3+) phosphate Chemical compound [Fe+3].[O-]P([O-])([O-])=O WBJZTOZJJYAKHQ-UHFFFAOYSA-K 0.000 description 1
- RUTXIHLAWFEWGM-UHFFFAOYSA-H iron(3+) sulfate Chemical compound [Fe+3].[Fe+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O RUTXIHLAWFEWGM-UHFFFAOYSA-H 0.000 description 1
- IEECXTSVVFWGSE-UHFFFAOYSA-M iron(3+);oxygen(2-);hydroxide Chemical compound [OH-].[O-2].[Fe+3] IEECXTSVVFWGSE-UHFFFAOYSA-M 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 229910000399 iron(III) phosphate Inorganic materials 0.000 description 1
- 229910000360 iron(III) sulfate Inorganic materials 0.000 description 1
- APVZWAOKZPNDNR-UHFFFAOYSA-L iron(ii) citrate Chemical compound [Fe+2].OC(=O)CC(O)(C([O-])=O)CC([O-])=O APVZWAOKZPNDNR-UHFFFAOYSA-L 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 239000000467 phytic acid Substances 0.000 description 1
- 229940068041 phytic acid Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- JHYAVWJELFKHLM-UHFFFAOYSA-H tetrasodium;2-hydroxypropane-1,2,3-tricarboxylate;iron(2+) Chemical compound [Na+].[Na+].[Na+].[Na+].[Fe+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O JHYAVWJELFKHLM-UHFFFAOYSA-H 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- WGIWBXUNRXCYRA-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WGIWBXUNRXCYRA-UHFFFAOYSA-H 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000011746 zinc citrate Substances 0.000 description 1
- 235000006076 zinc citrate Nutrition 0.000 description 1
- 229940068475 zinc citrate Drugs 0.000 description 1
- 239000011576 zinc lactate Substances 0.000 description 1
- 235000000193 zinc lactate Nutrition 0.000 description 1
- 229940050168 zinc lactate Drugs 0.000 description 1
- 229910000859 α-Fe Inorganic materials 0.000 description 1
Abstract
Description
本発明は、鉄塩、アスコルビン酸、亜鉛塩、糖アルコールを含有する経口組成物並びに鉄塩、アスコルビン酸及び亜鉛塩含有経口組成物の変色抑制方法に関する。 The present invention relates to an oral composition containing an iron salt, ascorbic acid, a zinc salt and a sugar alcohol, and a method for suppressing discoloration of an oral composition containing an iron salt, ascorbic acid and a zinc salt.
クエン酸第一鉄ナトリウム、グルコン酸第一鉄、硫酸第一鉄、フマル酸第一鉄、ピロリン酸第二鉄などの鉄塩は、鉄分の補給のための栄養機能食品や、鉄欠乏性貧血の治療用医薬品などとして広く使用されている。これらは保存時に特定の成分と共存させると、変色してしまい、外観の点で製品価値の低下を生じるという課題があり、とくに、鉄塩とビタミンCを組み合わせると変色が著しいことが知られている。しかし、鉄塩とビタミンCにさらに亜鉛塩が加わると、変色がさらに増強されることは知られていなかった。本発明者は、鉄塩とアスコルビン酸に亜鉛塩が加わると変色が増強されるという知見を得て、本発明者らが鋭意検討を重ねた結果、この亜鉛塩により増強される変色が特定の糖アルコールによって抑制できることを見出して完成させたものである。 Iron salts such as sodium ferrous citrate, ferrous gluconate, ferrous sulfate, ferrous fumarate, and ferric pyrophosphate are nutrient functional foods for iron supplementation and iron deficiency anemia. It is widely used as a therapeutic drug for iron. When these are coexisted with a specific component during storage, they discolor and have the problem of reducing the product value in terms of appearance. In particular, it is known that the discoloration is remarkable when iron salt and vitamin C are combined. There is. However, it was not known that the discoloration was further enhanced by the addition of zinc salt to iron salt and vitamin C. The present inventors have obtained the finding that the discoloration is enhanced when a zinc salt is added to an iron salt and ascorbic acid, and as a result of intensive studies by the present inventors, the discoloration enhanced by this zinc salt is specific. It was completed by discovering that it can be suppressed by sugar alcohol.
近年、ビタミンやミネラルなどの栄養機能成分を手軽に摂取することができると同時に、口腔内で味も楽しむことができる、チュアブルタイプの機能性食品の需要が高まっている。このような味質が大きく製品価値を左右する食品開発において、糖類は欠かすことができない素材であるが、保存時に他の成分と反応して変色してしまうという問題がある。糖アルコールは、反応性の高いカルボニル基が,水素添加(還元反応)によってアルコール性ヒドロキシ基に変化しているため、タンパク質やアミノ酸が共存する場合に起こる褐変,いわゆるメイラード反応を起こさないため、糖類の代替原料として幅広く利用されている。例えば、還元麦芽糖水飴(マルビット)は,スクロースに似た甘味質を示すことから、スクロース代替として食品全般で幅広く利用されている。 In recent years, there has been an increasing demand for chewable functional foods that can be easily ingested with nutritional functional ingredients such as vitamins and minerals and at the same time can be enjoyed in the oral cavity. Sugar is an indispensable material in food development where such taste quality greatly affects the product value, but there is a problem that it reacts with other components during storage and discolors. In sugar alcohol, a highly reactive carbonyl group is changed to an alcoholic hydroxy group by hydrogenation (reduction reaction), so that browning that occurs when proteins and amino acids coexist, that is, a so-called maillard reaction does not occur, so that sugar is a sugar. It is widely used as an alternative raw material for alcohol. For example, reduced maltose starch syrup (malbit) has a sweetness similar to that of sucrose, and is therefore widely used in all foods as a substitute for sucrose.
特許文献1(特開2017-109998号公報)は、クエン酸、酒石酸及びリンゴ酸などの有機酸を用いて、鉄化合物の変色を抑制する方法を開示している。 Patent Document 1 (Japanese Unexamined Patent Publication No. 2017-109998) discloses a method for suppressing discoloration of an iron compound by using an organic acid such as citric acid, tartaric acid and malic acid.
特許文献2(特開2008-54503号公報)は、果汁と、アスコルビン酸、クエン酸、フィチン酸、およびエタノールからなる群より選択される少なくとも3種と、ビタミンEとを組み合わせ、さらに糖アルコールを組み合わせることにより、脂質を多く含む青果物に対して特に優れた変色防止効果が得られる技術を開示している。 Patent Document 2 (Japanese Unexamined Patent Publication No. 2008-54503) combines fruit juice, at least three kinds selected from the group consisting of ascorbic acid, citric acid, phytic acid, and ethanol, and vitamin E, and further contains sugar alcohol. Disclosed is a technique for obtaining a particularly excellent anti-discoloration effect on fruits and vegetables containing a large amount of fat by combining them.
特許文献3(特開2000-197454号公報)は、特定の粒径の還元パラチノースを用いて、これとバインダー液とを適宜の造粒方法によって造粒した、ビタミンCあるいはこれと鉄分を含む粉粒体乃至錠剤により、鉄塩とビタミンCの組み合わせによる褐変を抑制する技術を開示している。 Patent Document 3 (Japanese Unexamined Patent Publication No. 2000-197454) describes vitamin C or a powder containing iron and vitamin C obtained by granulating this and a binder solution by an appropriate granulation method using reduced palatinose having a specific particle size. Disclosed is a technique for suppressing browning due to a combination of iron salt and vitamin C using granules or tablets.
これらの技術は、確かに変色を抑制する技術としては優れているが、鉄塩とアスコルビン酸に亜鉛塩が加わると変色が増強されるという本発明が有する独特の課題については、記載も示唆もされていない。
本発明は、亜鉛塩によって増強される鉄塩とアスコルビン酸の変色が特定の糖アルコールにより抑えられるという知見に基づき、新たな経口組成物を提案するものである。
These techniques are certainly excellent as techniques for suppressing discoloration, but the unique problem of the present invention that the discoloration is enhanced when a zinc salt is added to iron salt and ascorbic acid is described and suggested. It has not been.
The present invention proposes a new oral composition based on the finding that the discoloration of iron salt and ascorbic acid enhanced by a zinc salt is suppressed by a specific sugar alcohol.
本発明は、亜鉛塩により増強される鉄塩とアスコルビン酸との変色が抑制された経口組成物及びその変色抑制方法を提供することを課題とする。 An object of the present invention is to provide an oral composition in which discoloration of an iron salt enhanced by a zinc salt and ascorbic acid is suppressed, and a method for suppressing the discoloration thereof.
本発明の課題を解決するための手段は以下のとおりである。
1.以下の(A)~(D)を含有することを特徴とする経口組成物。
(A)鉄塩
(B)アスコルビン酸
(C)亜鉛塩
(D)エリスリトール、ソルビトール、キシリトールから選択される1以上
2.以下の(A)~(D)を含有させることを特徴とする経口組成物の変色抑制方法。
(A)鉄塩
(B)アスコルビン酸
(C)亜鉛塩
(D)エリスリトール、ソルビトール、キシリトールから選択される1以上
3.(A)鉄塩、(B)アスコルビン酸及び(C)亜鉛塩の合計質量に対する、(D)エリスリトール、ソルビトール、キシリトールから選択される1以上が、30質量%から1500質量%であることを特徴とする1.または2.に記載の経口組成物。
4.さらに、(E)アスコルビン酸以外の有機酸を含有することを特徴する1.~3.に記載の経口組成物。
5.経口組成物が、錠剤、チュアブル剤、細粒剤、顆粒剤、散剤およびカプセル剤から選択されるいずれかの形態であることを特徴とする、1.~4.のいずれかに記載の経口組成物。
The means for solving the problems of the present invention are as follows.
1. 1. An oral composition comprising the following (A) to (D).
(A) Iron salt (B) Ascorbic acid (C) Zinc salt (D) One or more selected from erythritol, sorbitol, and xylitol 2. A method for suppressing discoloration of an oral composition, which comprises the following (A) to (D).
(A) Iron salt (B) Ascorbic acid (C) Zinc salt (D) One or more selected from erythritol, sorbitol, and xylitol. It is characterized in that 1 or more selected from (D) erythritol, sorbitol, and xylitol is 30% by mass to 1500% by mass with respect to the total mass of (A) iron salt, (B) ascorbic acid and (C) zinc salt. 1. Or 2. Oral composition according to.
4. Further, (E) it is characterized by containing an organic acid other than ascorbic acid. ~ 3. Oral composition according to.
5. 1. The oral composition is characterized in that it is in any form selected from tablets, chewables, fine granules, granules, powders and capsules. ~ 4. The oral composition according to any one of.
本発明の経口組成物によって、亜鉛塩により増強される鉄塩とアスコルビン酸との変色が抑制され、外観上にも優れた経口組成物を提供することができる。 The oral composition of the present invention suppresses the discoloration of the iron salt and ascorbic acid enhanced by the zinc salt, and can provide an oral composition having an excellent appearance.
本発明の経口組成物は、(A)鉄塩、(B)アスコルビン酸、(C)亜鉛塩および(D)エリスリトール、ソルビトール、キシリトールから選択される1以上を含有することを特徴とする。 The oral composition of the present invention is characterized by containing one or more selected from (A) iron salt, (B) ascorbic acid, (C) zinc salt and (D) erythritol, sorbitol, xylitol.
((A)鉄塩)
鉄は、生命を維持する上で不可欠な栄養素のひとつであり、鉄の摂取不足は、貧血症、胃腸障害、思考力低下などを引き起こす。本発明に用いる鉄塩は、1種のみを用いても良いし、2種以上を混合しても良い。本発明に用いる鉄塩は、植物や動物、魚介類、鉱物等より抽出、精製して得られた天然由来のものや、化学的もしくは酵素反応を利用して合成したものを用いることができる。本発明に用いる鉄塩としては、例えば、塩化鉄、塩化第二鉄、クエン酸第一鉄、クエン酸第二鉄、リン酸第二鉄、ピロリン酸第一鉄、ピロリン酸第二鉄、硫酸第一鉄、硫酸第二鉄、水酸化第二鉄、クエン酸アンモニウム第二鉄、グルコン酸第一鉄、乳酸鉄等が挙げられるが、味質、吸収性や安全性の観点から、クエン酸第一鉄、クエン酸第二鉄、ピロリン酸第一鉄、ピロリン酸第二鉄が特に好ましい。食品用として市販されているものであれば、特に制限されずに使用できる。
((A) Iron salt)
Iron is one of the essential nutrients for sustaining life, and insufficient intake of iron causes anemia, gastrointestinal disorders, and decreased thinking ability. As the iron salt used in the present invention, only one kind may be used, or two or more kinds may be mixed. As the iron salt used in the present invention, naturally derived iron salts obtained by extracting and purifying from plants, animals, fish and shellfish, minerals and the like, and those synthesized by chemical or enzymatic reactions can be used. Examples of the iron salt used in the present invention include iron chloride, ferric chloride, ferrous citrate, ferric citrate, ferric phosphate, ferrous pyrophosphate, ferric pyrophosphate, and sulfuric acid. Examples thereof include ferrous iron, ferric sulfate, ferric hydroxide, ferric ammonium citrate, ferrous gluconate, iron lactate, etc., but citric acid is used from the viewpoint of taste, absorbability and safety. Ferrite, ferric citrate, ferrous pyrophosphate, and ferric pyrophosphate are particularly preferred. Anything commercially available for food can be used without particular limitation.
((B)アスコルビン酸)
本発明に用いる(B)アスコルビン酸は、アスコルビン酸塩を含まない概念である。ただし、本発明の機能を損なわない限り、本発明の経口組成物中にアスコルビン酸塩が含有されていてもよい。食品用として市販されている原料であれば、特に制限されずに使用することができる。
((B) Ascorbic acid)
(B) Ascorbic acid used in the present invention is a concept that does not contain ascorbic acid salt. However, ascorbic acid salt may be contained in the oral composition of the present invention as long as the function of the present invention is not impaired. Any raw material commercially available for food can be used without particular limitation.
((C)亜鉛塩)
亜鉛は、ヒトや生物にとって必須の微量ミネラルであり、味覚を正常に保ち、皮膚や粘膜の健康維持にも不可欠な栄養素である。食品に用いられる亜鉛としては、亜鉛塩や、酵母の培養液中に亜鉛塩を添加して酵母に亜鉛を取り込ませて亜鉛を強化した亜鉛酵母などが挙げられ、通常、亜鉛酵母には亜鉛塩はほとんど残留しない。本発明に用いる亜鉛塩としては、塩化亜鉛、硫酸亜鉛、グルコン酸亜鉛、乳酸亜鉛、クエン酸亜鉛などが例示でき、グルコン酸亜鉛、硫酸亜鉛、塩化亜鉛が好ましく、グルコン酸亜鉛がとくに好ましく、これらから選択される1種以上を混合して使用することができる。
((C) Zinc salt)
Zinc is an essential trace mineral for humans and living organisms, and is an essential nutrient for maintaining normal taste and maintaining the health of skin and mucous membranes. Examples of zinc used in foods include zinc salts and zinc yeasts obtained by adding zinc salts to yeast culture solutions to allow yeast to take up zinc and fortify zinc. Usually, zinc yeasts are zinc salts. Almost does not remain. Examples of the zinc salt used in the present invention include zinc chloride, zinc sulfate, zinc gluconate, zinc lactate, zinc citrate, and the like, zinc gluconate, zinc sulfate, and zinc chloride are preferable, and zinc gluconate is particularly preferable. One or more selected from the above can be mixed and used.
((D)エリスリトール、ソルビトール、キシリトールから選択される1以上)
本発明に用いるエリスリトール、ソルビトール、キシリトールは、これらから選択される1種以上を混合して使用することができる、亜鉛塩により増強される鉄塩とアスコルビン酸との変色を抑制できる観点で、エリスリトール、ソルビトール、キシリトールが好ましく、エリスリトール、キシリトールがとくに好ましい。食品用として市販されている原料であればとくに制限なく使用することができる。
((D) One or more selected from erythritol, sorbitol, and xylitol)
The erythritol, sorbitol, and xylitol used in the present invention can be used as a mixture of one or more selected from these, and erythritol can suppress the discoloration of the iron salt enhanced by the zinc salt and ascorbic acid. , Sorbitol and xylitol are preferable, and erythritol and xylitol are particularly preferable. Any raw material commercially available for food can be used without particular limitation.
((E)アスコルビン酸以外の有機酸)
本発明に用いる(E)アスコルビン酸以外の有機酸として、変色をより抑制できる点で、クエン酸、酒石酸及びリンゴ酸から選択される1以上を含有するが好ましく、クエン酸を含有することが特に好ましい。
((E) Organic acid other than ascorbic acid)
As the organic acid other than (E) ascorbic acid used in the present invention, it is preferable to contain one or more selected from citric acid, tartaric acid and malic acid in that discoloration can be further suppressed, and it is particularly preferable to contain citric acid. preferable.
本発明の経口組成物に用いる(D)エリスリトール、ソルビトール、キシリトールから選択される1以上の含有量として、本発明の経口組成物の味質を損なわない範囲であれば特に制限されないが、(A)鉄塩、(B)アスコルビン酸及び(C)亜鉛塩の合計質量に対する、(D)エリスリトール、ソルビトール、キシリトールから選択される1以上の質量が、甘味度と変色をより抑制できる観点で、30質量%から1500質量%であることが好ましく、80質量%から1400質量%であることがより好ましい。 The content of 1 or more selected from (D) erythritol, sorbitol, and xylitol used in the oral composition of the present invention is not particularly limited as long as it does not impair the taste quality of the oral composition of the present invention, but (A). 30) From the viewpoint that the mass of 1 or more selected from (D) erythritol, sorbitol, and xylitol with respect to the total mass of iron salt, (B) ascorbic acid and (C) zinc salt can further suppress sweetness and discoloration. It is preferably from% by mass to 1500% by mass, more preferably from 80% by mass to 1400% by mass.
また、本発明の経口組成物に用いる(E)アスコルビン酸以外の有機酸の含有量として、本発明の経口組成物の味質を損なわない範囲であれば特に制限されないが、(A)鉄塩、(B)アスコルビン酸及び(C)亜鉛塩の合計質量に対する、(E)アスコルビン酸以外の有機酸の質量が、1質量%から100質量%であることが好ましく、10質量%から80質量%であることがより好ましい。 The content of the organic acid other than (E) ascorbic acid used in the oral composition of the present invention is not particularly limited as long as it does not impair the taste of the oral composition of the present invention, but (A) an iron salt. , The mass of the organic acid other than (E) ascorbic acid is preferably 1% by mass to 100% by mass, preferably 10% by mass to 80% by mass, based on the total mass of (B) ascorbic acid and (C) zinc salt. Is more preferable.
本発明の経口組成物の形態としては、通常の食品形態やサプリメント形態でもよく、サプリメント形態としては、錠剤、チュアブル剤、顆粒剤、カプセル剤などの固形製剤、ドリンク剤、ゼリー剤、グミ剤などの液剤などの形態で経口により投与することができるが、鉄や亜鉛を継続して摂取するための簡便さの観点から、錠剤、チュアブル剤、細粒剤、顆粒剤、散剤およびカプセル剤が好ましく、錠剤、チュアブル剤、カプセル剤がさらに好ましい。任意成分としては、例えば、賦形剤、結合剤、被覆剤、滑沢剤、糖衣剤、崩壊剤、増量剤、矯味矯臭剤、乳化・可溶化・分散剤、安定剤、pH調整剤、等張剤などが挙げられる。これらを常法に従って処理することにより、本発明の経口組成物を製造することができる。 The form of the oral composition of the present invention may be a normal food form or a supplement form, and the supplement form may be a solid preparation such as a tablet, a chewable agent, a granule or a capsule, a drink agent, a jelly agent, a gummy agent or the like. Although it can be administered orally in the form of a liquid, tablets, chewables, fine granules, granules, powders and capsules are preferable from the viewpoint of convenience for continuous ingestion of iron and zinc. , Tablets, chewables, capsules are more preferred. Optional components include, for example, excipients, binders, coatings, lubricants, sugar coatings, disintegrants, bulking agents, flavoring agents, emulsifying / solubilizing / dispersing agents, stabilizers, pH adjusters, etc. Examples include tensioning agents. By treating these according to a conventional method, the oral composition of the present invention can be produced.
以下、本願発明者らが行った試験であって、該発明者らが、以下の(A)~(D)を含有することを特徴とする経口組成物が、優れた変色抑制効果を有するという知見を得た試験について説明する。
(A)鉄塩
(B)アスコルビン酸
(C)亜鉛塩
(D)エリスリトール、ソルビトール、キシリトールから選択される1以上
本発明を実施例に基づいて詳細に説明するが、これに限定されるものではない。
Hereinafter, the test conducted by the inventors of the present application, wherein the oral composition containing the following (A) to (D) is said to have an excellent discoloration suppressing effect. The test for which the findings were obtained will be described.
(A) Iron salt (B) Ascorbic acid (C) Zinc salt (D) One or more selected from erythritol, sorbitol, and xylitol The present invention will be described in detail based on examples, but is not limited thereto. not.
<Hunter Lab表色系について>
本明細書中「Hunter Lab表色系(Lab表色系)」とは、色度を示すa軸及びb軸よりなる直交座標とこれに垂直なL軸とから構成される色立体を成す表色系である。ここで、「L*値」とは明度を数値で表した値であり、L*値=100の時は白色となり、L*値=0の時は黒色となる。本発明に用いる経口組成物において、鉄塩とアスコルビン酸との反応により変色する場合、ならびに亜鉛塩によりこの鉄塩とアスコルビン酸との変色が増強する場合、黒く変色するため、時間の経過とともにL*値は小さい値へと変化する。
また、「a*値」とは赤色と緑色の色調を数値で表現した値である。a*値の+の値が大きいほど赤色が強くなり、a*値の-の値が大きいほど緑色が強くなる。「b*値」とは黄色と青色の色調を数値で表現した値である。b*値の+の値が大きいほど黄色が強くなり、b*値の-の値が大きいほど青色が強くなることを示す。
<About the Hunter Lab color system>
In the present specification, the "Hunter Lab color system (Lab color system)" is a table forming a color solid composed of orthogonal coordinates consisting of a-axis and b-axis indicating chromaticity and an L-axis perpendicular to the orthogonal coordinates. It is a color system. Here, the "L * value" is a value expressing the brightness numerically, and is white when the L * value = 100 and black when the L * value = 0. In the oral composition used in the present invention, when the color changes due to the reaction between the iron salt and ascorbic acid, and when the discoloration between the iron salt and ascorbic acid is enhanced by the zinc salt, the color changes to black. * The value changes to a smaller value.
The "a * value" is a numerical value expressing the color tones of red and green. The larger the + value of the a * value, the stronger the red color, and the larger the negative value of the a * value, the stronger the green color. The "b * value" is a numerical value expressing the color tones of yellow and blue. The larger the + value of the b * value, the stronger the yellow color, and the larger the negative value of the b * value, the stronger the blue color.
実施例1~11、比較例1~10として、各成分を表1~5に示す質量比で配合し、粉末状組成物(表1~3,5)もしくは錠剤(表4の比較例9,10、実施例8)を調製し、以下の通りLab表色系におけるL*値の測定ならびに、官能評価を実施した。なお、調製した錠剤は、ユニパック(チャック付きポリ袋)に充填し、5℃、60%RH、若しくは25℃、60%RHで4日間保管した。 In Examples 1 to 11 and Comparative Examples 1 to 10, each component was blended in the mass ratios shown in Tables 1 to 5, and powdered compositions (Tables 1 to 3, 5) or tablets (Comparative Examples 9 and 9 in Table 4) were blended. 10. Example 8) was prepared, and the measurement of the L * value in the Lab color system and the sensory evaluation were carried out as follows. The prepared tablets were packed in a unipack (plastic bag with a zipper) and stored at 5 ° C., 60% RH, or 25 ° C., 60% RH for 4 days.
<装置、及び条件>
表1~3,5に示した粉末状組成物および表4に示した錠剤を分光測色計(コニカミノルタ社製CHROMA METER CR-5;測定タイプはシャーレ測定、測定径はφ30mm)を用いてL*値を測定した。
<Device and conditions>
The powdered compositions shown in Tables 1 to 3 and 5 and the tablets shown in Table 4 were measured using a spectrophotometer (CHROMA MTER CR-5 manufactured by Konica Minolta Co., Ltd .; measurement type was Petri dish measurement, measurement diameter was φ30 mm). The L * value was measured.
<粉末状組成物のHunter Lab表色系の測定方法>
表1~3、5に記載の粉末状組成物に水を2mL滴下後、プラ製の棒で撹拌し、経時的にL*値を測定した。
<Measelling method of Hunter Lab color system of powdery composition>
After 2 mL of water was added dropwise to the powdery compositions shown in Tables 1 to 3 and 5, the mixture was stirred with a plastic rod, and the L * value was measured over time.
<錠剤のHunter Lab表色系の測定方法>
表4に記載の錠剤を2粒ずつシャーレに入れてL*値を測定した。
<Measelling method of Hunter Lab color system of tablets>
Two tablets shown in Table 4 were placed in a petri dish and the L * value was measured.
使用した各成分は、以下の通りである。なお、粉末状組成物、錠剤は常法により調製した。
エリスリトール(エリスリトールT微粉、三菱ケミカルフーズ株式会社)
トレハロース(トレハ微粉、株式会社林原)
キシリトール(キシリトール50M、物産フードサイエンス株式会社)
マルチトール(アマルティMR-50、三菱商事ライフサイエンス株式会社)
ソルビトール(ソルビトールTBS、物産フードサイエンス株式会社)
Each component used is as follows. The powdery composition and tablets were prepared by a conventional method.
Erythritol (Erythritol T Fine Powder, Mitsubishi Chemical Foods Co., Ltd.)
Trehalose (Trehalose fine powder, Hayashibara Co., Ltd.)
Xylitol (Xylitol 50M, Bussan Food Science Co., Ltd.)
Maltitol (Amarti MR-50, Mitsubishi Shoji Life Science Co., Ltd.)
Sorbitol (Sorbitol TBS, Bussan Food Science Co., Ltd.)
(錠剤の官能試験)
訓練された専門官能検査員により、調製した錠剤の外観について、5℃保管品に比べた場合の25℃保管した錠剤を下記の基準で評価を行った。
なお、錠剤はアルミ袋から5粒ずつ取り出したときの評価である。
〇:全く変色していない、ほとんど変色していない、若しくは錠剤を隣り合わせに並べなければ違いが分からない程度にわずかに変色している。
×:錠剤を隣り合わせに並べなくても違いが分かる程度に変色している、かなり変色している。
(Sensory test of tablets)
The appearance of the prepared tablets was evaluated by a trained professional sensory inspector according to the following criteria for the tablets stored at 25 ° C as compared with the products stored at 5 ° C.
It should be noted that the tablets are evaluated when 5 tablets are taken out from the aluminum bag.
〇: No discoloration at all, almost no discoloration, or slight discoloration to the extent that the difference cannot be seen unless the tablets are arranged side by side.
X: The color is discolored to the extent that the difference can be seen even if the tablets are not arranged side by side, and the color is considerably discolored.
(結果) (result)
Claims (5)
(A)鉄塩
(B)アスコルビン酸
(C)亜鉛塩
(D)エリスリトール、ソルビトール、キシリトールから選択される1以上 An oral composition comprising the following (A) to (D).
(A) Iron salt (B) Ascorbic acid (C) Zinc salt (D) One or more selected from erythritol, sorbitol, and xylitol
(A)鉄塩
(B)アスコルビン酸
(C)亜鉛塩
(D)エリスリトール、ソルビトール、キシリトールから選択される1以上 A method for suppressing discoloration of an oral composition, which comprises the following (A) to (D).
(A) Iron salt (B) Ascorbic acid (C) Zinc salt (D) One or more selected from erythritol, sorbitol, and xylitol
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020186436A JP2022076151A (en) | 2020-11-09 | 2020-11-09 | Oral composition with suppressed discoloration, and method for suppressing discoloration thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020186436A JP2022076151A (en) | 2020-11-09 | 2020-11-09 | Oral composition with suppressed discoloration, and method for suppressing discoloration thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2022076151A true JP2022076151A (en) | 2022-05-19 |
Family
ID=81606765
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020186436A Pending JP2022076151A (en) | 2020-11-09 | 2020-11-09 | Oral composition with suppressed discoloration, and method for suppressing discoloration thereof |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2022076151A (en) |
-
2020
- 2020-11-09 JP JP2020186436A patent/JP2022076151A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1152766B1 (en) | Vitamin compatible micronutrient supplement | |
JP2983503B2 (en) | Iron-calcium mineral supplement with high bioavailability | |
KR0151138B1 (en) | Gourd powder composition | |
JP7092774B2 (en) | Iron-enriched food composition | |
CN101208015A (en) | Food composition for binding acetaldehyde in the mouth and in digestive track and method for preparation of the composition | |
JPH0124768B2 (en) | ||
JP5224680B2 (en) | Anti-fatigue | |
CN101253947A (en) | Nutritive composition for adult pet cat | |
JP2008088101A (en) | Antifatigue agent | |
JP2022076151A (en) | Oral composition with suppressed discoloration, and method for suppressing discoloration thereof | |
JP6045784B2 (en) | Preparation containing hard-to-color pyrroloquinoline quinones | |
EP1135110B1 (en) | Preparation of dry compositions soluble in the presence of water and avoiding maillard reaction in dry state and uses | |
JP2938009B1 (en) | Green tea paste | |
US9474292B1 (en) | Nutritional powder including brewer's yeast, aronia extract, and cranberry extract for animals | |
US20070027214A1 (en) | Orally administered agent for improving skin condition | |
JP2002265359A (en) | Kainic acid type glutamate receptor-shielding agent, ampa type glutamate receptor shielding agent, brain- protecting agent and food or drink having brain- protecting function | |
JP3763801B2 (en) | Mineral-containing liquid, method for producing the same and product using the same | |
JP2022076152A (en) | Oral composition with suppressed discoloration and method for suppressing discoloration thereof | |
JP2012170342A (en) | Taste quality improver | |
KR102549896B1 (en) | Capsule containing pyrroloquinolinequinone or a salt thereof and branched-chain amino acids | |
KR102405534B1 (en) | Lipase Inhibition and Fishy Inhibition Method of Fish by Hyperhydrostatic Treatment | |
JPH05292918A (en) | Functional health food | |
RU2420097C1 (en) | Food product | |
JP4722492B2 (en) | An agent for preventing or ameliorating indefinite complaints associated with iron deficiency anemia. | |
US20060258746A1 (en) | Oral medicament for improvement in going to sleep or waking |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230612 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20240417 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240423 |